Navigation Links
Precyse Solutions Launches Clinical Documentation Improvement Program to Assist Hospitals in Accelerating Revenues
Date:4/15/2008

Precyse Enhances Its CDI Program Utilizing the Expertise of Two Industry

Veterans

WAYNE, Pa., April 15 /PRNewswire/ -- Precyse Solutions, the leader in driving peak performance within Health Information Management (HIM) departments, has added even more depth to its already robust service offerings and highly qualified team of HIM experts. Noted professionals Sue Muse, RHIA and Deborah Worthington, RHIT have been recruited to lead and implement the development of Precyse's Clinical Documentation Improvement (CDI) Program. The Precyse Program provides a mechanism for communication and collaboration among physicians, nurses, coders and other integral members of the healthcare team to secure complete clinical information that most accurately reflects the illness and treatment of the patient. Customers who fully deploy this program will experience the most appropriate and accurate coding and MS- DRG assignment resulting in appropriate and complete reimbursement for care delivered. By eliminating coding errors and improving clinical documentation, Precyse's CDI Program avoids delays in reimbursement, ultimately accelerating revenue received.

With over 25 years in the healthcare industry, Sue Muse has been named Director of CDI at Precyse, where she will oversee the entire scope of Precyse's CDI services including managing CDI implementation and ensuring client deliverables and client expectations are met or exceeded. Prior to joining Precyse, Sue re-established a complete CDI program for Pikeville Medical Center starting in 2002 where she made significant contributions and enhancements to their existing program, The Pikeville Program, which consisted of compliance, organizational profiling and improved documentation for the continuum of care, and yielded significant results for the hospital.

Deborah Worthington, a Coding Compliance and Education Senior Consultant with Precyse, recently received the newly announ
'/>"/>

SOURCE Precyse Solutions
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Precyse Solutions Promotes Ken Lacy to Senior Vice President & CIO to Drive Advancement of PrecyseNet(TM), Precyses Advanced Technology Solution
2. Precyse Executive Authors New Book, The Legal Health Record
3. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
4. Rising Medical Solutions and WorkCompEDI Establish Relationship to Provide Workers Compensation eBilling Solutions
5. HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project
6. Medco Acquires Majority Interest in Europa Apotheek; Delivering Innovation, Clinical Quality and Lower-Cost Solutions to Fast-Growing German Health Care Market
7. Accuro Healthcare Solutions Acquires TPMS
8. MedQuist Technology Solutions to Power Documentation Workflow at New England Facility
9. SXC Health Solutions to Present at the Suntrust 37th Annual Institutional Conference
10. UHW Outlines Solutions to Californias Health Crisis
11. Cardinal Health, ClearCount Medical Solutions Sign Primary Distribution Agreement for RFID-Enabled Sponge Counting, Detection System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... Kids, parents and schools need to work together t... FRIDAY, Nov. 21 (HealthDay News) -- Behavior that...cognized as bullying. , And as mounting researc... the victim, mental-health professionals, schools,...th new ways to combat this threatening behavior. ...
(Date:11/21/2008)..., HOUSTON(Nov. 21, 2008)The University of Texas He...rogram, Training Excellence in Aging Studies (TEXA...through a prestigious $2 million award from the Do...atching funds., "This will allow us to teach geri...t junior medical student to practicing physicians....
(Date:11/21/2008)... TUCSON, Ariz., Nov. 21 ...C ) today announced that Craig A. Norris, the Comp... to the Company,s Board of,Directors. Mr. Norris...2008,resignation of Steven I. Geringer and return...serve on any committee of the Board. , Mr. ...
(Date:11/21/2008)... Trials showed Banzel proved effective against Len... (HealthDay News) -- A new drug called Banzel (ruf...tment for a severe form of epilepsy called Lennox-...ation announced Friday. , The approval was base...ncluded patients ages 4 to 30. Compared to patient...
Breaking Medicine News(10 mins):Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2
...t the Shanghai Children’s Medical Center have succ...rare, well-developed third arm from a two-month-ol...t arms that had been laid across Liu Junjie's ches...is further up his shoulder. ‘We found the nerves ...
... Health Organisation has ruled out human-to-human ...esian nurses tending patients with the disease // ...he ability to spread more readily among humans. 'T...nurses provide reassuring evidence that the virus ...
... drug used to treat chronic myeloid leukemia has s...f patients with the cancer.// The National Institu...h regulates drug approvals in the UK had only want...s, but the drug has not proved itself in clinical ...
...ight is back on drugs and high life in Mumbai with...hospital, and Sahil Zarru, who is suspected to hav...arty circuit here. "Cocaine, ecstasy, acid and her...rugs,are a rage with the rich and the famous in Mu...
Other Medicine News:Health News:Drugs Part of Mumbai High Life 2
(Date:11/20/2008)... Calif., Nov. 20 Milk. It does a b...originally thought. After years of,research, scie...es found in,cow,s milk that stimulate the body,s ...ew the Multimedia News Release, go to:, http://www... While developing new cancer therapies, the chie...
(Date:11/20/2008)...Nov. 20 Clinical data from a prosp...nnual Veith Symposium shows DVT,treatment with th...us,Vascular, Inc. (Santa Clara, CA) successfully ...t 20 minutes. , This technique, called isol...ood flow more quickly and safely than current cath...
(Date:11/19/2008)...AKS, Calif., Nov. 19 Amg...ncology Company, a subsidiary of,Takeda Pharmaceu... that,enrollment in the Phase 3 MONET1 trial eval...clitaxel and carboplatin for the first-line treatm...) has been temporarily suspended,following a plan...
(Date:11/19/2008)...l., Nov. 19 Isogen, a contract dev...le filling, today announced the first,phase launc... founded to,specifically address the process, fac...ith the $2 billion highly-niched, low-volume clini...rket segment. , Companies can invest over $...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Isogen Launches Major New Facility to Address Global Biopharma Demand 2New Program Website Targets Jewish Children Teens and Adults Suffering from the Impact of Childhood Maltreatment 20926 1New Program Website Targets Jewish Children Teens and Adults Suffering from the Impact of Childhood Maltreatment 20926 2Ferndale and Foamix Execute License Agreement for Development of Non Steroidal Foam for Atopic Dermatitis 5760 1Ferndale and Foamix Execute License Agreement for Development of Non Steroidal Foam for Atopic Dermatitis 5760 2Chronic Stomach Inflammation Boosts Cancer Risk 20924 1Chronic Stomach Inflammation Boosts Cancer Risk 20924 2Canine Cancer Web Exclusive for Dog Owners and Lovers Presented by Morris Animal Foundation Features Colorado State and Cornell University Veterina 20919 1Canine Cancer Web Exclusive for Dog Owners and Lovers Presented by Morris Animal Foundation Features Colorado State and Cornell University Veterina 20919 2
...ieves All Key Endpoints for Both Efficacy and Safe...rstCall/ --,Indevus Pharmaceuticals, Inc. today an...inetic trial for NEBIDO (testosterone,undecanoate)...nder,development for the treatment of male hypogon...ng Pharma AG, Germany. The data,from the recently ...
... is evaluating zonisamide SR as a novel component ... June 07, 2007 /PRNewswire-FirstCall/ -- Orexigen(...ny focused on the,treatment of central nervous sys...day announced results from a Phase I trial evaluat...rietary,sustained-release (SR) formulation of zon...
Other Medicine Technology:Indevus Reports Positive Data From Phase III NEBIDO Trial 2Indevus Reports Positive Data From Phase III NEBIDO Trial 3Indevus Reports Positive Data From Phase III NEBIDO Trial 4Indevus Reports Positive Data From Phase III NEBIDO Trial 5Indevus Reports Positive Data From Phase III NEBIDO Trial 6OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry.
BD Vacutainer® Specialty Tubes - Sedimentation Rate Determination (SRD)
Inquire
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
Medicine Products: